Trial Profile
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Kadmon Corporation; Sanofi
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 09 Apr 2018 Planned End Date changed from 1 Sep 2019 to 1 Jun 2019.
- 09 Apr 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2019.